SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.

Eichelberg C, Vervenne WL, De Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenmüller C, Zimmermann U, Bos MM, Freier W, Schirrmacher-Memmel S, Staehler M, Pahernik S, Los M, Schenck M, Flörcken A, van Arkel C, Hauswald K, Indorf M, Gottstein D, Michel MS.

Open source

DOI: 10.1016/j.eururo.2015.04.017
Published: 2015-05-04
Container: Eur Urol
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.eururo.2015.04.017,
  title = {SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.},
  author = {Eichelberg C and  Vervenne WL and  De Santis M and  Fischer von Weikersthal L and  Goebell PJ and  Lerchenmüller C and  Zimmermann U and  Bos MM and  Freier W and  Schirrmacher-Memmel S and  Staehler M and  Pahernik S and  Los M and  Schenck M and  Flörcken A and  van Arkel C and  Hauswald K and  Indorf M and  Gottstein D and  Michel MS.},
  year = {2015},
  journal = {Eur Urol},
  doi = {10.1016/j.eururo.2015.04.017},
  url = {https://doi.org/10.1016/j.eururo.2015.04.017}
}

RIS

TY  - JOUR
TI  - SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
AU  - Eichelberg C
AU  -  Vervenne WL
AU  -  De Santis M
AU  -  Fischer von Weikersthal L
AU  -  Goebell PJ
AU  -  Lerchenmüller C
AU  -  Zimmermann U
AU  -  Bos MM
AU  -  Freier W
AU  -  Schirrmacher-Memmel S
AU  -  Staehler M
AU  -  Pahernik S
AU  -  Los M
AU  -  Schenck M
AU  -  Flörcken A
AU  -  van Arkel C
AU  -  Hauswald K
AU  -  Indorf M
AU  -  Gottstein D
AU  -  Michel MS.
PY  - 2015
JO  - Eur Urol
DO  - 10.1016/j.eururo.2015.04.017
UR  - https://doi.org/10.1016/j.eururo.2015.04.017
ER  -

APA

C, E., WL, V., M, D. S., L, F. V. W., PJ, G., C, L., U, Z., MM, B., W, F., S, S., M, S., S, P., M, L., M, S., A, F., C, V. A., K, H., M, I., D, G., & MS., M. (2015). SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.. Eur Urol. https://doi.org/10.1016/j.eururo.2015.04.017

Source records

europe-pmc · retrieved 2026-09-26T06:49:18.813Z